MedTrace Logo

Comparison of Adding EMEND to PONV/PDNV Treatment Regimen

NCT01186029 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-08-30

No results posted yet for this study

Summary

This study is looking at whether the addition of Aprepitant (Emend), an antiemetic, will provide added efficacy if added to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

aprepitant

Emend 40mg by mouth 30 minutes before procedure x 1

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Maria A Michaelis, MD · University of Nebraska

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-01
Primary Completion
2011-09-01
Completion
2011-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01186029 on ClinicalTrials.gov